Adaptive Biotechnologies Corporation (ADPT)
ADPT Stock Price Chart
Explore Adaptive Biotechnologies Corporation interactive price chart. Choose custom timeframes to analyze ADPT price movements and trends.
ADPT Company Profile
Discover essential business fundamentals and corporate details for Adaptive Biotechnologies Corporation (ADPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jun 2019
Employees
619.00
Website
https://www.adaptivebiotech.comCEO
Chad M. Robins
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Financial Timeline
Browse a chronological timeline of Adaptive Biotechnologies Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.18, while revenue estimate is $58.91M.
Earnings released on 5 Aug 2025
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $58.88M , beating expectations by +6.28%.
Earnings released on 1 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.28 by +28.57%, while revenue for the quarter reached $52.44M , beating expectations by +24.49%.
Earnings released on 11 Feb 2025
EPS came in at -$0.23 surpassing the estimated -$0.27 by +14.81%, while revenue for the quarter reached $47.46M , beating expectations by +3.06%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%, while revenue for the quarter reached $46.44M , beating expectations by +15.48%.
Earnings released on 1 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%, while revenue for the quarter reached $43.19M , beating expectations by +6.46%.
Earnings released on 7 May 2024
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $41.87M , beating expectations by +7.98%.
Earnings released on 14 Feb 2024
EPS came in at -$0.30 surpassing the estimated -$0.32 by +6.25%, while revenue for the quarter reached $45.78M , missing expectations by -5.52%.
Earnings released on 9 Nov 2023
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%, while revenue for the quarter reached $37.92M , missing expectations by -11.73%.
Earnings released on 2 Aug 2023
EPS came in at -$0.33 matching the estimated -$0.33, while revenue for the quarter reached $48.93M , beating expectations by +8.99%.
Earnings released on 3 May 2023
EPS came in at -$0.40 falling short of the estimated -$0.34 by -17.65%, while revenue for the quarter reached $37.65M , beating expectations by +2.27%.
Earnings released on 14 Feb 2023
EPS came in at -$0.28 surpassing the estimated -$0.37 by +24.32%, while revenue for the quarter reached $55.20M , beating expectations by +0.87%.
Earnings released on 3 Nov 2022
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%, while revenue for the quarter reached $47.83M , beating expectations by +0.04%.
Earnings released on 3 Aug 2022
EPS came in at -$0.37 surpassing the estimated -$0.40 by +7.50%, while revenue for the quarter reached $43.66M , beating expectations by +4.43%.
Earnings released on 4 May 2022
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%, while revenue for the quarter reached $38.62M , beating expectations by +2.24%.
Earnings released on 15 Feb 2022
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $37.93M , beating expectations by +4.30%.
Earnings released on 3 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.43 by +6.98%, while revenue for the quarter reached $39.47M , beating expectations by +6.47%.
Earnings released on 4 Aug 2021
EPS came in at -$0.35 surpassing the estimated -$0.43 by +18.60%, while revenue for the quarter reached $38.51M , beating expectations by +23.18%.
Earnings released on 5 May 2021
EPS came in at -$0.29 surpassing the estimated -$0.41 by +29.27%, while revenue for the quarter reached $38.44M , beating expectations by +38.53%.
Earnings released on 24 Feb 2021
EPS came in at -$0.33 falling short of the estimated -$0.30 by -10.00%, while revenue for the quarter reached $30.19M , beating expectations by +16.00%.
Earnings released on 10 Nov 2020
EPS came in at -$0.27 surpassing the estimated -$0.28 by +3.57%, while revenue for the quarter reached $26.30M , missing expectations by -3.45%.
ADPT Stock Performance
Access detailed ADPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.